Cargando…

ER-α36: a novel biomarker and potential therapeutic target in breast cancer

Estrogen receptor-alpha36 (ER-α36) is a 36-kDa variant of estrogen receptor-alpha (ER-α) firstly identified and cloned by Wang et al in 2005. It lacks both transactivation domains (activation function 1 and activation function 2) and has different biological characteristics compared to traditional E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Xingyun, Xu, Xin, Li, Guangliang, Lin, Bingyi, Cao, Jiang, Teng, Lisong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155893/ https://www.ncbi.nlm.nih.gov/pubmed/25210466 http://dx.doi.org/10.2147/OTT.S65345

Ejemplares similares

ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway
por: Li, Guangliang, et al.
Publicado: (2020)

The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors
por: Gu, Yu, et al.
Publicado: (2014)

ERα-36 regulates progesterone receptor activity in breast cancer
por: Konan, Henri-Philippe, et al.
Publicado: (2020)

ER-α36-Mediated Rapid Estrogen Signaling Positively Regulates ER-Positive Breast Cancer Stem/Progenitor Cells
por: Deng, Hao, et al.
Publicado: (2014)

Huaier polysaccharide inhibits the stem-like characteristics of ERα-36(high) triple negative breast cancer cells via inactivation of the ERα-36 signaling pathway
por: Hu, Baoquan, et al.
Publicado: (2019)

GPRC5A: An Emerging Biomarker in Human Cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2018)

Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer
por: Gu, Yu, et al.
Publicado: (2016)

Deciphering of a Putative GPER Recognition Domain in ERα and ERα36
por: Acramel, Alexandre, et al.
Publicado: (2022)

The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancer
por: Omarjee, S, et al.
Publicado: (2017)

Dual Epigenetic Regulation of ERα36 Expression in Breast Cancer Cells
por: Thiebaut, Charlène, et al.
Publicado: (2019)

Therapeutic Potential for Targeting Autophagy in ER+ Breast Cancer
por: Finnegan, Ryan M., et al.
Publicado: (2022)

The Role of ERα36 in Development and Tumor Malignancy
por: Thiebaut, Charlène, et al.
Publicado: (2020)

From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression
por: Chamard-Jovenin, Clémence, et al.
Publicado: (2015)

Novel interactions between ERα-36 and STAT3 mediate breast cancer cell migration
por: Xiang, Yuan, et al.
Publicado: (2019)

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression
por: Pan, Xiaohua, et al.
Publicado: (2022)

A Positive Feedback Loop of ER-α36/EGFR Promotes Malignant Growth of ER-negative Breast Cancer Cells
por: Zhang, XianTian, et al.
Publicado: (2010)

Chaperone gp96 mediates ER-α36 cell membrane expression
por: Hou, Junwei, et al.
Publicado: (2015)

Diagnostic value of BRAF(V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis
por: Su, Xingyun, et al.
Publicado: (2016)

Bioinformatics Identification of TUBB as Potential Prognostic Biomarker for Worse Prognosis in ERα-Positive and Better Prognosis in ERα-Negative Breast Cancer
por: Alhammad, Rashed
Publicado: (2022)

Advances in the targeted therapy of liposarcoma
por: Guan, Zhonghai, et al.
Publicado: (2015)

ERα36-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer
por: Nagel, Anna, et al.
Publicado: (2022)

YAP inhibits ERα and ER(+) breast cancer growth by disrupting a TEAD-ERα signaling axis
por: Li, Xu, et al.
Publicado: (2022)

A Systematic In Silico Mining of the Mechanistic Implications and Therapeutic Potentials of Estrogen Receptor (ER)-α in Breast Cancer
por: Li, Xin, et al.
Publicado: (2014)

Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36
por: Shen, Yingying, et al.
Publicado: (2018)

ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway
por: Zhu, Linlin, et al.
Publicado: (2018)

Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets
por: Beumers, Lukas, et al.
Publicado: (2023)

The potential antiepileptogenic effect of neuronal Cx36 gap junction channel blockage
por: Wang, Guangliang, et al.
Publicado: (2021)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis
por: Su, Xingyun, et al.
Publicado: (2016)

ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways
por: Lin, Sheng-Li, et al.
Publicado: (2010)

N-α-PGP and PGP, potential biomarkers and therapeutic targets for COPD
por: O'Reilly, Philip, et al.
Publicado: (2009)

Tamoxifen enhances stemness and promotes metastasis of ERα36(+) breast cancer by upregulating ALDH1A1 in cancer cells
por: Wang, Qiang, et al.
Publicado: (2018)

Cyanidin-3-o-glucoside directly binds to ERα36 and inhibits EGFR-positive triple-negative breast cancer
por: Wang, Li, et al.
Publicado: (2016)

The essential role of YAP in ERα36-mediated proliferation and the epithelial-mesenchymal transition in MCF-7 breast cancer cells
por: Park, Miso, et al.
Publicado: (2022)

COL12A1, a novel potential prognostic factor and therapeutic target in gastric cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2019)

Decoding the Therapeutic Implications of the ERα Stability and Subcellular Distribution in Breast Cancer
por: Tecalco-Cruz, Angeles C., et al.
Publicado: (2022)

Cyclin genes as potential novel prognostic biomarkers and therapeutic targets in breast cancer
por: Liu, Nian-Qiu, et al.
Publicado: (2022)

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets
por: Gates, Leah A., et al.
Publicado: (2018)

ER-α36, a Novel Variant of ER-α, Mediates Estrogen-Stimulated Proliferation of Endometrial Carcinoma Cells via the PKCδ/ERK Pathway
por: Tong, Jing-Shan, et al.
Publicado: (2010)

ER-α36-mediated gastric cancer cell proliferation via the c-Src pathway
por: WANG, XUMING, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ae7alfa94njqarpnoprkqvjhdn